Loading clinical trials...
Loading clinical trials...
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Conditions
Interventions
NeuVax vaccine
Trastuzumab
+1 more
Locations
24
United States
Sarcoma Oncology Research Center, LLC
Santa Monica, California, United States
St Joseph Heritage Healthcare
Santa Rosa, California, United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
University of Miami
Deerfield Beach, Florida, United States
Memorial Breast Cancer Center
Hollywood, Florida, United States
University of Miami
Kendall, Florida, United States
Start Date
October 1, 2014
Primary Completion Date
December 1, 2021
Completion Date
December 1, 2021
Last Updated
December 12, 2023
NCT04541381
NCT05468034
NCT03137095
NCT07040891
NCT06393374
NCT07547774
Lead Sponsor
Cancer Insight, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions